The ISPE Foundation announced Gilead Sciences, Inc. (Gilead) is partnering with the Foundation to establish a new Technology Without Borders initiative. This new program was created to fill a critical gap in the availability of ISPE's Guidance Documents and the necessary training to adopt this guidance into practice in countries where socioeconomic conditions or language barriers may otherwise limit access.
NORTH BETHESDA, Md., Oct. 28, 2022 /PRNewswire-PRWeb/ -- The ISPE Foundation announced Gilead Sciences, Inc. (Gilead) is partnering with the Foundation to establish a new Technology Without Borders initiative. This new program was created to fill a critical gap in the availability of ISPE's Guidance Documents and the necessary training to adopt this guidance into practice in countries where socioeconomic conditions or language barriers may otherwise limit access.
Gilead's generous support of the Technology Without Borders program will be applied towards the translation of biotechnology-relevant ISPE Guidance Documents and delivery of the respective technical training to the local workforce, academia, and key stakeholders in Brazil. ISPE International will fully manage the dissemination of all Guidance Documents and deliver all training.
"A capable and skilled workforce is required for medicines developed by the pharmaceutical industry across the globe and the ever-advancing technologies used in their development. Often, they need access to Guidance Documents, training, and information in various languages, facilitating the transmission of this knowledge," said Antonio Moreira, Vice-Provost, Academic Affairs, University of Maryland, Baltimore County and the 2022-2024 ISPE Foundation Board Chair. "My vision for the Technology Without Borders program is to not only make the technology and information accessible but then to work with the key stakeholders in these regions so there is an ecosystem of highly skilled people who can help support the further development and implementation of this knowledge."
"Gilead is committed to bringing transformative medicines to patients worldwide and is pleased to partner with the ISPE Foundation on the Technology Without Borders initiative to support these efforts," said Joydeep Ganguly, Senior Vice President of Corporate Operations at Gilead Sciences. "Educational equity and knowledge exchange are critical to the success of the pharmaceutical industry. We are delighted to partner with ISPE on a program that enables broad access to core engineering standards and best practices, making them more readily available in emerging economy markets."
About the ISPE Foundation
The ISPE Foundation, the philanthropic arm of ISPE International, is a tax-exempt 501(c)(3) organization that supports ISPE's interests across the globe. Specific programs within the foundation include Workforce of the Future, Women in Pharma®, and the Global Knowledge Exchange.
The ISPE Foundation is supported by an International Board of Directors and a global staff of association professionals and advisers under the leadership of Board Chair Dr. Antonio Moreira and ISPE's President & CEO, Thomas Hartman. As an indication of their level of commitment, 100% of Board Members have contributed donations to support Foundation initiatives. Funded by the generosity of our donors, the Foundation champions programs that create opportunity, diversity, and success within the global pharmaceutical industry.
About Gilead
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, intending to create a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California, USA.
Media Contact
Kristin LeMunyon, ISPE, 1-813-960-2105, [email protected]
SOURCE ISPE
![](https://rt.prnewswire.com/rt.gif?NewsItemId=UN18655&Transmission_Id=202210281500PR_NEWS_USPR_____UN18655&DateId=20221028)
Share this article